Aptorum Group Ltd - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
APM Nasdaq 2834 http://www.aptorumgroup.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aptorum Group Ltd

What Kind Of Shareholders Hold The Majority In Aptorum Group Limited's (NASDAQ:APM) Shares? - Jul 15th, 2021 6:03 am
Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate - Jul 12th, 2021 12:59 pm
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus - Jul 12th, 2021 12:00 pm
Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report - Jul 9th, 2021 12:00 pm
Commvault Named 2021 HPE GreenLake Momentum Partner of the Year - Jun 22nd, 2021 8:00 pm
GigaOm Radar Reports Name Commvault a "Leader" and "Outperformer" for Hybrid Cloud Data Protection in Enterprise and SMB Categories; Commvault Rated Top Performer Across All Categories in Both Reports - Jun 21st, 2021 12:30 pm
Aptorum Group CEO Subscribed Shares In The Company - May 26th, 2021 12:00 pm
Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock - May 24th, 2021 4:03 pm
Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study - May 24th, 2021 3:57 pm
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma - May 24th, 2021 12:00 pm
Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference - May 13th, 2021 11:00 am
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions - May 6th, 2021 11:00 am
Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report. - Apr 23rd, 2021 3:35 pm
Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications - Apr 22nd, 2021 1:04 pm
Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases - Apr 22nd, 2021 11:00 am
Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update - Apr 19th, 2021 11:00 am
Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA) - Mar 31st, 2021 11:00 am
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Jan 20th, 2021 12:32 pm
Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) - Jan 20th, 2021 11:00 am
Could The Aptorum Group Limited (NASDAQ:APM) Ownership Structure Tell Us Something Useful? - Jan 16th, 2021 6:23 am